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S616 Journal of Thoracic Oncology Vol. 13 No. 10Stimes for diagnosis and treatment were calculated. Result: Patient
characteristics are shown in Table 1. Median wait times for investiga-
tion and treatment are shown in Table 2. There were variations be-
tween centres and regions. Conclusion: To our knowledge, this is the
largest multicentre review of wait times for diagnosis and treatment of
lung cancer with detailed characteristics of patients. Data will be
completed and updated prior to the meeting, to try to identify specific
factors associated with longer wait times. Keywords: diagnosis, treat-
ment, wait times
Characteristic No (%)
Age, years, mean (range) 68.5 (20-94)
Male sex 585 (48)
Smoking status Former or current smoker
Never smoker Unknown
1120 (92) 60 (5) 37 (3)
ECOG performance status 0 1 2 Missing 416 (34) 358 (30)
393 (32) 50 (4)
Histology
Adenocarcinoma 631 (52)
Squamous cell carcinoma 284 (23)








Limited SCLC 40 (3)
Extensive SCLC 138 (11)
Missing 10 (1)
Known positive EGFR mutation status (n¼395
tested) Known positive ALK translocation status
(n¼387 tested) PD-L1 TPS (n¼386 tested) <1%
1-49% 50% Number of investigations per patient,
median (IQR)
28 (7) 6 (2) 85 (22)
151 (39) 150 (39)
7 (6, 8)
Tumor board review 194 (16)
Final diagnostic procedure
Flexible bronchoscopy 338 (28)
EBUS/EUS 223 (18)
Transthoracic needle biopsy 301 (25)
Thoracoscopy 139 (11)
Biopsy of metastatic site 145 (12)
Sputum cytology 1 (0)
Thoracentesis 61 (5)
Mediastinoscopy Missing 2 (0) 7 (1)ECOG ¼ Eastern Cooperative Oncology Group; NSCLC ¼ non-small cell lung
cancer; NOS ¼ not otherwise specified; SCLC ¼ small cell lung cancer; EGFR
¼ epidermal growth factor receptor; ALK ¼ anaplastic lymphoma kinase;
TPS ¼ tumor proportion score; IQR ¼ interquartile range; EBUS ¼ endo-
bronchial ultrasonography; EUS ¼ endoscopic ultrasonography.
Table 2. Median wait times for investigation and
treatment
Median wait,
Investigation or treatment interval Pts (n) days (IQR)Referral to first appointment with specialist 972 2 (0, 7)
First appointment to diagnosis 1152 18 (8, 43)
Diagnosis to first treatment 930 22 (5, 42)
Referral to first treatment 737 58 (28, 89)
Abnormal imaging to first treatment 902 72 (39, 111)
Surgery 268 109 (80, 142)
Radiation 362 59 (28, 98)
Systemic therapy 330 62 (35, 92)P1.15-14
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Background:We analyzed the prevalence of pneumonia in lung cancer
survivors using claims data from the Health Insurance Review and
Assessment Service (HIRA) in South Korea. Method: We defined
pneumonia among a nationwide cohort of 173,390 patients who were
diagnosed with lung cancer and underwent surgery from January 1,
2010 to December 31, 2014, based on HIRA claim data. Descriptive
statistics were calculated to estimate the frequency of pneumonia using
diagnostic code and utilization pattern at medical institutions. Result:
Thirty two thousand five hundred lung cancer survivors (19.8%) were
diagnosed with pneumonia. The overall frequency of influenza
increased from February (n¼8089) and peaked in May (n¼9,654).
Over 59.06% (57,979) of claims for pneumonia treatment were in the
clinic, whereas general hospitals accounted for 40.94% (40,184).
Among 101,351 claims, admission rate increased as patients get older
and the average length of hospitalization was 4.8 days. Elderly breast
cancer survivors over 70 years old had the longest length of hospital-
ization at 6.2 days. Conclusion: Lung cancer survivors are more sus-
ceptible to pneumonia than non-cancer survivors. It is important not
only to raise the vaccination rate among young cancer survivors, but
also to quickly identify symptoms and begin treatment for pneumonia
in elderly cancer survivors.
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Background: Afatinib, a second-generation epidermal growth factor
receptor (EGFR)-tyrosine kinase inhibitor (TKI) is the recommended
first-line treatment for patients with advanced non-small cell lung
cancer harbouring sensitizing EGFRmutations. The role of afatinib after
failure of first-generation EGFR-TKIs is controversial. Method: A
retrospective observational study of patients with EGFR mutant
advanced NSCLC receiving second-line afatinib after failure of first-
generation EGFR-TKI in University Malaya Medical Center from 1st
December 2014 to 30th April 2018. Result: The demographic and
clinical characteristics of 27 patients treated with afatinib after failure
of first-generation EGFR-TKI are shown in Table 1. Twenty-three pa-
tients received gefitinib and 4 patients received erlotinib as first-line
treatment. The mPFS with first-line treatment was 11.9 months. Fifteen
patients had progression of disease (PD) following second-line afatinib
with mPFS of 4.2 months and median time-to-treatment failure of 5.7
months. The mPFS2 conferred by first-line first-generation EGFR-TKI
and second-line afatinib was 18.4 months. The overall response rate to
second-line afatinib was 18.5% (5/27) while the disease control rate as
70.3% (19/27). Two patients who had PD on first-generation EGFR-TKI
due to T790M mutation received second-line afatinib while waiting for
compassionate access to osimertinib. Nine of the 15 patients (69.2%)
with PD on afatinib underwent investigations for resistance mecha-
nisms. Three patients had T790M mutation, one of whom had
October 2018 Abstracts S617concomitant small cell lung cancer transformation. c-MET amplification
was detected in another 3 patients. One patient each had EML4-ALK
rearrangement and epithelial mesenchymal transition. Conclusion:
Afatinib conferred a modest mPFS benefit after failure of first-genera-
tion EGFR-TKI. The mPFS of sequential treatment with first-generation
EGFR-TKI followed by afatinib seems longer than the mPFS of first-line
afatinib in phase 3 randomised controlled trials. Apart from T790M
mutation, the resistance mechanisms to second-line afatinib in our
patients are more heterogenous. Keywords: afatinib, resistance
mechanism, second line treatment
P1.15-16
ALKConnect: An Anaplastic Lymphoma Kinase Positive
(ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient
Insights NetworkH. Lin,1 X. Pan,1 H. Huang,1 G. Salvatore,1 S. Clarke,2 H. West3
1Millennium Pharmaceuticals, Inc., A Wholly Owned Subsidiary of Takeda
Pharmaceutical Company Limited, Cambridge/MA/US, 2Invitae
Corporation, San Francisco/CA/US, 3Thoracic Oncology Program,
Swedish Cancer Institute, Seattle/WA/US
Background: ALK+ NSCLC is a subset of NSCLC present in w3-5% of
NSCLC patients. Little is known about ALK+ NSCLC patients’ unique
journeys, their perspectives on the burden of disease, and their ‘real-
world’ treatment experiences. Online patient networks provide op-
portunities to gain valuable insights into outcomes meaningful to pa-
tients, directly from patients. The objective of this study is to develop
an ALK+ NSCLC patient network to facilitate patient interaction and to
conduct patient-centered research including understanding unmet
needs, patient preferences, health-related quality of life (HRQoL), and
product differentiation. Method: The ALKConnect Patient Insights
Network (www.alkconnect.com) will be a patient-focused registry that
directly collects information from patients living with ALK+ NSCLC.
Patients meeting study criteria will be enrolled in the online survey
over a 2-year period. Inclusion criteria are US, adult, English-speakingpatients with ALK+ NSCLC providing written, informed consent,
internet access, and willing to answer regular e-surveys. Retrospective
and cross-sectional ‘real-world’ data that will be collected include de-
mographics, clinical characteristics including ALK+ NSCLC disease
history and status, comorbidities, past and present treatment experi-
ences and outcomes, quality of life, patient preferences, healthcare
resource use, and work productivity. Supplementary data may be
collected through uploading of electronic medical records. Result: The
ALKConnect Patient Insights Network will systematically characterize
the natural history of ALK+ NSCLC and its treatment and the overall
impact on patients. The data collected will be reported descriptively for
the population overall and by subgroups of interest (e.g., age, sex)
where sample sizes permit. The associations between treatment his-
tory/disease status and patient-reported outcomes including symptom
severity, HRQoL (e.g., responses to the MD Anderson Symptom In-
ventory lung cancer module [MDASI-LC]), healthcare resource use, and
work productivity will be analyzed. Longitudinal trends will be evalu-
ated to enable a better understanding of the impact of ALK+ NSCLC
over time. All de-identified information gathered from ALKConnect will
be shared with the ALK+ NSCLC community, including patients, care-
givers, healthcare professionals, advocacy organizations, and fellow
researchers. Conclusion: We present ALKConnect, an online ALK+
NSCLC patient insights network directly from patients. ALKConnect
will provide patients with ALK+ NSCLC opportunities to share their
treatment experiences, disease burden, HRQoL, and preferences.
Through dissemination to scientific and medical communities,
researchers will gain first-hand insights into ALK+ NSCLC patients’
experiences of care, and into opportunities for addressing patients’
unmet needs. Keywords: Patient-reported outcomes, Real-world
treatment, ALKConnect
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Background: Postoperative radiotherapy (PORT) of complete
resected stage IIIA non-small cell lung cancer with N2 nodal
